LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Metadata referenced Lineage Cell Therapeutics, but filing text identifies BioTime, Inc.)
Reporting Period: Quarterly period ended March 31, 2002 (Form 10-Q)
Business Stage: Development stage biomedical company focused on synthetic plasma expanders (Hextend), blood volume substitutes (PentaLyte), and organ preservation solutions (HetaCool).
Primary Revenue Source: Royalties from Abbott Laboratories on sales of Hextend in the U.S. and Canada.

Key Financial Metrics

Debt Obligations: $3,350,000 in debentures (net of discount: $1,824,601) due August 1, 2004, bearing 10% interest. A new $300,000 line of credit was established on March 27, 2002.

Material Changes vs. Prior Period

• Revenue Growth: Royalty revenue increased 75% to $57,235 from $32,695 in the prior year quarter, driven by increased Hextend sales by Abbott Laboratories.
• Expense Reduction: Total expenses decreased significantly to $591,978 from $990,889. Research and Development (R&D) expenses dropped 53% to $260,571, and General and Administrative (G&A) expenses fell 24% to $331,407.
• Cost Cutting Measures: The reduction in expenses is attributed to a concerted effort to cut spending, including reduced funding for lab equipment, consultants, and clinical trials. Additionally, the workforce was reduced from 11 to 8 full-time employees, with remaining staff agreeing to voluntary salary reductions ranging from 14% to 78%.
• Interest Expense: Net interest expense was $171,665, compared to net interest income of $6,455 in the prior year, due to the issuance of debentures in August 2001.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Needs: Management believes existing cash ($987,470) and credit facilities are sufficient to operate through December 31, 2002. However, the company requires additional capital to continue operations, begin clinical trials for PentaLyte, and fund R&D.
• Spending Restrictions: Debenture terms restrict quarterly operating cash payments to $450,000 plus cash revenue collected. The company is prohibited from paying dividends or repurchasing shares until debentures are paid in full.
• Product Pipeline:
  • Hextend: Sales are in a ramp-up phase; recognized royalties for Q1 2002 sales will be reported in Q2 2002. Military interest in the product is growing.
  • PentaLyte: Phase I clinical trial completed; planning next phase for hypovolemia treatment in surgery.
  • HetaCool: Research program launched for low-temperature surgery and organ preservation.
• Risks: Success depends on obtaining regulatory approvals (FDA), securing additional financing (which may cause dilution), and achieving revenue levels adequate to support the cost structure. Failure to raise capital could force the company to curtail or suspend operations.

Investor Verification Checklist

• Cash Runway: Verify if the company has secured the additional equity capital needed to extend operations beyond the projected December 31, 2002 date.
• Debt Covenants: Monitor compliance with the $450,000 quarterly operating expense cap imposed by debenture holders.
• Revenue Timing: Confirm the lag in royalty recognition (Q1 sales recognized in Q2) and the actual sales volume of Hextend by Abbott Laboratories.
• Regulatory Milestones: Track progress on FDA filings for PentaLyte and HetaCool, as well as Canadian regulatory approvals for Hextend.
• Dilution Risk: Assess the impact of potential future equity offerings or warrant exercises (515,385 warrants outstanding from debentures) on shareholder value.